Clinical trials: System Sclerosis
Relapsing Remitting Multiple Sclerosis, Secondary-progressive Multiple Sclerosis
Improving Cognitive Aptitudes With tDCS in Patients With Multiple Sclerosis
Noninvasive brain stimulations (NIBS) will be used in MS patients with cognitive impairments to enhance their cognitive aptitudes.
- Conditions
- Relapsing Remitting Multiple Sclerosis, Secondary-progressive Multiple Sclerosis, Cognitive Deficits, Motor Deficits
- Trial name
- MScog-tDCS (NCT02266121)
- Testing
- tDCS
- Where
- Belgium
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- University Hospital of Mont-Godinne
Multiple Sclerosis, Relapsing-Remitting
Monitoring of Patients Followed for a Multiple Sclerosis and Treated by Dimethyl-fumarate
The dimethyl fumarate is an oral drug, indicated in the treatment of the relapsing-remitting multiple sclerosis (MS) , which efficacy and safety has been assessed and validated in two randomised, placebo phase-controlled III…
- Trial name
- SURV-SEP (NCT02901106)
- Testing
- Dimethyl fumarate
- Where
- France
- Volunteers
- 11 people
- Sponsor
- Fondation Ophtalmologique Adolphe de Rothschild
Relapsing Remitting Multiple Sclerosis
Study To Evaluate The Immunogenicity And Safety Of r-hIFN Beta-1a (Rebif®) Using Clone 484-39 In Multiple Sclerosis
The objectives of the study are: comparison of the incidence and time course of the development of neutralizing antibodies (NAbs) to Rebif after 48 weeks of therapy, to historical data from Serono clinical trial databases to…
- Trial name
- NCT00367484
- Testing
- Rebif® (clone 484-39)
- Volunteers
- 460 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Systemic Sclerosis, Scleroderma
Safety, Tolerability, and Pharmacokinetics of CAT-192 (Human Anti-TGF-Beta1 Monoclonal Antibody) in Patients With Early Stage Diffuse Systemic Sclerosis
Systemic Sclerosis (also known as Scleroderma) is a chronic, autoimmune disease of the connective tissue generally classified as one of the rheumatic diseases.
- Trial name
- NCT00043706
- Testing
- Human Anti-Transforming Growth Factor Beta-1 Monoclonal Antibody
- Where
- 4 sites in United States
- Sponsor
- Genzyme, a Sanofi Company
Multiple Sclerosis
Combined Exercise Training in Patients With Multiple Sclerosis
It is stated that the affected cognitive functions in Multiple Sclerosis are learning, memory, attention, speed of information processing, visuospatial skills, and executive functions.
- Trial name
- NCT03591809
- Testing
- combined exercise training
- Where
- Turkey (Türkiye)
- Volunteers
- 17 people
- Sponsor
- Gazi University
Amyotrophic Lateral Sclerosis
Dexpramipexole Japanese PK Study
This is a single and multiple dose, open-label study to evaluate the pharmacokinetics (PK), safety, and tolerability of dexpramipexole administered orally to adult Japanese and Caucasian healthy subjects.
- Trial name
- NCT01424163
- Testing
- Single dose reduced, Single dose standard, Multiple Dose
- Where
- United Kingdom
- Volunteers
- 57 people, healthy volunteers welcome
- Sponsor
- Knopp Biosciences
Cultural Adaptation, Reliability
Turkish Version of F-2-MS
The aims of this study were to perform cultural adaptation of the F-2-MS and provide information regarding the factor structure, reliability and validity of the instrument in Turkish speaking patients with Multiple Sclerosis.
- Conditions
- Cultural Adaptation, Reliability, Validity, Multiple Sclerosis
- Trial name
- NCT05590533
- Testing
- Cultural adaptation, reliability and validity
- Volunteers
- 180 people
- Sponsor
- Pamukkale University
Amyotrophic Lateral Sclerosis, Neuromuscular Diseases
Breath Stacking Technique Associated With Expiratory Muscle Training in Amyotrophic Lateral Sclerosis Patients
it will be conducted a randomized parallel controlled trial with patients diagnosed with Amyotrophic Lateral Sclerosis (ALS) to compare two techniques to lung recruitment and cough augmentation, to assess their effects on…
- Trial name
- NCT04226144
- Testing
- Breath Stacking Group, Breath stacking and EMT
- Where
- Brazil
- Volunteers
- 50 people
- Sponsor
- Escola Superior de Ciencias da Saude
Amyotrophic Lateral Sclerosis
Salivary Biomarker Discovery by Raman Spectroscopy in ALS (SalivALS)
BACKGROUND/RATIONALE: The paucity of biomarkers for the diagnosis and monitoring of patients affected by Amyotrophic Lateral Sclerosis (ALS) is one of the greatest concerns in ALS clinics and research.
- Trial name
- SalivALS (NCT04233099)
- Testing
- Raman analysis of saliva with data collection and analysis
- Where
- 2 sites in Italy
- Volunteers
- 126 people, healthy volunteers welcome
- Sponsor
- Fondazione Don Carlo Gnocchi ETS
Amyotrophic Lateral Sclerosis
Intraventricular Transplantation of Mesenchymal Stem Cell in Patients With ALS
ALS is a debilitating disease with varied etiology characterized by rapidly progressive weakness, muscle atrophy and fasciculations, muscle spasticity, difficulty speaking (dysarthria), difficulty swallowing (dysphagia), and…
- Trial name
- NCT01759784
- Testing
- Intraventricular injection
- Where
- Iran
- Sponsor
- Royan Institute
Tuberous Sclerosis Complex, TSC Related Cognitive Disability
Efficacy of RAD001/Everolimus in Autism and NeuroPsychological Deficits in Children With Tuberous Sclerosis Complex
Tuberous sclerosis complex (TSC) is a genetic disease that leads to mental retardation in over 50% of patients, and to learning problems, behavioral problems, autism and epilepsy in up to 90% of patients.
- Conditions
- Tuberous Sclerosis Complex, TSC Related Cognitive Disability, TSC Related Autism, TSC Related Learning Problems
- Trial name
- RAPIT (NCT01730209)
- Testing
- Everolimus
- Where
- Netherlands
- Volunteers
- 60 people
- Sponsor
- Erasmus Medical Center
Multiple Sclerosis
The 'Wearing Off' Effect of DMT
This is a non-interventional, cross-sectional, qualitative study in which patients diagnosed with MS and clinicians with experience treating MS will be interviewed regarding patient experiences with the wearing off effect from…
- Trial name
- NCT05627271
- Testing
- ocrelizumab, natalizumab, ofatumumab
- Where
- Switzerland
- Volunteers
- 39 people
- Sponsor
- Novartis Pharmaceuticals
Multiple Sclerosis, Relapsing-Remitting
An Observational Study to Evaluate Quality of Life (QoL) and Influence of Cognitive Status on QoL in Patients With Relapsing-Remitting Multiple Sclerosis (RRMS) During 2 Years Treatment With Rebif New Formulation (RNF)
This is a prospective, non-interventional, multicenter study to evaluate quality of life (QoL) and influence of cognitive status on QoL in subjects with relapsing-remitting multiple sclerosis (RRMS) during two years of treatment…
- Trial name
- MusiClock (NCT01110993)
- Where
- Poland
- Volunteers
- 65 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Motor Neuron Disease, Primary Lateral Sclerosis
Oxidative Stress in Motor Neuron Disease: COSMOS Add-On Study
Background: Primary lateral sclerosis (PLS) is a disorder in which nerve cells in the brain that control movement degenerate. The cause of PLS is not known, but some research has suggested that environmental factors that produce…
- Trial name
- NCT01143428
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
Localized Scleroderma
Photobiomodulation in Children With Localized Scleroderma
to evaluate the efficacy of the Polarized light therapy and Hand Grip Strengthening exercises in patients with CREST syndrome
- Trial name
- NCT06621628
- Testing
- Study Group A, Study GrouB, Study Group C
- Where
- 2 sites in Egypt
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- New Ismailia National University
Relapsing-Remitting Multiple Sclerosis, Fatigue
Effects of Tysabri (BG00002) Over 12 Months on MS Related Fatigue in Participants With RRMS
The primary objective of this trial is to observe the Multiple Sclerosis (MS) related fatigue during treatment with Tysabri as measured by changes in the fatigue scale for motor and cognitive functions (FMSC) over the course of…
- Trial name
- TYNERGY (NCT00884481)
- Testing
- Natalizumab
- Where
- 27 sites in Austria, Denmark and 2 more
- Volunteers
- 195 people
- Sponsor
- Biogen
Relapsing Remitting Multiple Sclerosis
Evaluate Safety/Tolerability in Portuguese Participants With RRMS Transitioning From Current Therapy
The primary objective of the study is to evaluate safety and tolerability as defined by the frequency of the adverse events (AEs) of flu-like symptoms (FLS) [chills, pyrexia, myalgia, and asthenia], injection site reactions…
- Trial name
- PLENO (NCT03177083)
- Testing
- peginterferon beta-1a, interferon beta-1a, interferon beta-1b
- Where
- 15 sites in Portugal
- Volunteers
- 80 people
- Sponsor
- Biogen
Multiple Sclerosis
BrainAgeMS - a Comparative Study of Brain Aging in Healthy and Patients With Multiple Sclerosis
The purpose of this study is to investigate new quantitative MRI-sequences for assessment of age-specific data for the prediction of brain aging.
- Trial name
- BrainAgeMS (NCT06221631)
- Where
- Switzerland
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Insel Gruppe AG, University Hospital Bern
Multiple Sclerosis (MS)
A Study to Explore Association Patterns Between Digital Outcome Assessments From the Konectom™ Platform and Magnetic Resonance Imaging (MRI) Measures of Brain Tissue Damage
The purpose of the study is to explore association patterns between digital outcome assessments from Konectom and MRI measures of brain tissue damage.
- Trial name
- NCT05106465
- Testing
- Konectom platform
- Where
- Germany
- Volunteers
- 200 people
- Sponsor
- Biogen
Multiple Sclerosis
Long Term Study of Fingolimod in MS Patients From the FTY Clinical Program
The purpose of this observational study is to collect long-term data on safety and effectiveness of fingolimod, particularly including clinical disease and patient outcome related parameters such as relapse and disability, in…
- Trial name
- NCT01281657
- Testing
- fingolimod
- Where
- 58 sites in United States, Canada
- Volunteers
- 64 people
- Sponsor
- Novartis
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.